Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
self-reported symptoms of OAB for ≥ 3 months prior to screening
OAB as defined by urinary frequency (a minimum of 8 micturitions per 24 hours)
urgency (defined as a strong and sudden desire to urinate) or urge incontinence a minimum of 2 episodes in 3 days, as confirmed by the micturition diary between screening and baseline
patients who describe the degree of bothersomeness of their most bothersome OAB symptom as "moderately ", "a great deal ", or "a very great deal" per the OAB Bother Rating Scale
You may not be if
any condition that would contraindicate their usage of tolterodine once daily, including: narrow angle glaucoma, urinary retention, gastric retention
any clinically significant local urinary tract pathology which could mimic the symptoms of OAB, such as infection or hematuria
stress incontinence, functional, or overflow incontinence as determined by the investigator
symptomatic acute urinary tract infection (UTI) during the run-in period, or recurrent UTIs defined by treatment for symptomatic UTI \>3 times in the 12 months prior to participation in this clinical trial
clinically significant urinary tract obstruction
history of lower urinary tract surgery (e.g. prostate removal or destruction, incontinence surgery) within the past 3 months
clinically significant interstitial cystitis or significant bladder pain syndrome
Clareo Health | A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
